» Articles » PMID: 5485144

A Third Class of Anti-arrhythmic Action. Effects on Atrial and Ventricular Intracellular Potentials, and Other Pharmacological Actions on Cardiac Muscle, of MJ 1999 and AH 3474

Overview
Journal Br J Pharmacol
Publisher Wiley
Specialty Pharmacology
Date 1970 Aug 1
PMID 5485144
Citations 71
Authors
Affiliations
Soon will be listed here.
Abstract

1. Both MJ 1999 and AH 3474 protected guinea-pigs anaesthetized with urethane against ouabain-induced ventricular fibrillation.2. MJ 1999 had 1/90, and AH 3474 1/30, of the activity of procaine in reducing the height of the action potential of frog sciatic nerve.3. MJ 1999 and AH 3474 reduced the rate of rise of intracellularly recorded action potentials at concentrations in excess of 160 x 10(-6)M (50 mg/l.). It was concluded that direct depression of depolarization could have contributed little to the protection against ouabain-induced fibrillation.4. MJ 1999, but not AH 3474, greatly prolonged the duration of the action potential in acute experiments on isolated atrial and ventricular muscle, and prolonged the Q-Tc interval of the electrocardiogram in anaesthetized guinea-pigs. It is suggested that this effect contributes to anti-arrhythmic activity.5. At concentrations up to 80 x 10(-6)M AH 3474 had positive chronotropic and inotropic effects on isolated rabbit atrial muscle, but at higher concentrations these were superseded by negative effects. MJ 1999 was depressant at all concentrations studied, the threshold concentrations being 19 x 10(-6)M for chronotropic, and 162 x 10(-6)M for inotropic effects.

Citing Articles

A Comparative Study of the Rapid (I) and Slow (I) Delayed Rectifier Potassium Currents in Undiseased Human, Dog, Rabbit, and Guinea Pig Cardiac Ventricular Preparations.

Agoston M, Kohajda Z, Virag L, Balati B, Nagy N, Lengyel C Pharmaceuticals (Basel). 2024; 17(8).

PMID: 39204196 PMC: 11357539. DOI: 10.3390/ph17081091.


The Future of Antiarrhythmic Drug Therapy: Will Drugs Be Entirely Replaced by Procedures?.

Valderrabano M Methodist Debakey Cardiovasc J. 2022; 18(5):58-63.

PMID: 36561081 PMC: 9733159. DOI: 10.14797/mdcvj.1185.


Cardiac hERG K Channel as Safety and Pharmacological Target.

Su S, Sun J, Wang Y, Xu Y Handb Exp Pharmacol. 2021; 267:139-166.

PMID: 33829343 DOI: 10.1007/164_2021_455.


Why translation from basic discoveries to clinical applications is so difficult for atrial fibrillation and possible approaches to improving it.

Nattel S, Sager P, Huser J, Heijman J, Dobrev D Cardiovasc Res. 2021; 117(7):1616-1631.

PMID: 33769493 PMC: 8208745. DOI: 10.1093/cvr/cvab093.


Influence of Amiodarone and Dronedarone on the Force-Interval Dependence of Rat Myocardium.

Kondratieva D, Afanasiev S, Popov S Biomed Res Int. 2018; 2018:4737489.

PMID: 30155479 PMC: 6098862. DOI: 10.1155/2018/4737489.


References
1.
Lish P, WEIKEL J, Dungan K . Pharmacological and toxicological properties of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1965; 149(2):161-73. View

2.
STANTON H, Kirchgessner T, Parmenter K . Cardiovascular pharmacology of two new beta-adrenergic receptor antagonists. J Pharmacol Exp Ther. 1965; 149(2):174-82. View

3.
Levy J, Richards V . Inotropic and metabolic effects of three beta-adrenergic receptor blocking drugs on isolated rabbit left atria. J Pharmacol Exp Ther. 1965; 150(3):361-9. View

4.
ARAMENDIA P, Kaumann A . Inhibition of sympathomimetic effects on the cardiovascular system by 4-(2-isopropylamino-1-hydroxyethyl)methanesulfonanilide hydrochloride (MJ 1999). J Pharmacol Exp Ther. 1967; 155(2):259-66. View

5.
Schmid J, Hanna C . A comparison of the antiarrhythmic actions of two new synthetic compounds, iproveratril and MJ 1999, with quinidine and pronethalol. J Pharmacol Exp Ther. 1967; 156(2):331-8. View